Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 19, 2009

View Archived Issues

Johnson & Johnson reports third quarter 2009 results

BIBW-2948 not well tolerated in 4-week chronic obstructive pulmonary disease study

ADC-4022 given with budesonide protects lung function in COPD patients

Alimera Sciences completes 2-year patient follow-up for phase III Iluvien trial in DME

Provectus expands compassionate use program of PV-10 to cancer patients in U.S.

Pfizer completes acquisition of Wyeth

ZyStor Therapeutics cleared by FDA to start phase I trial of ZC-701 in Pompe disease

FDA recommends approval of Acorda Therapeutics' Fampridine-SR for MS

CSC and FSMA complete pre-IND meeting with FDA for stem cell-derived therapy for SMA

Moxaverine increases ocular blood flow in macular degeneration, glaucoma patients

Medarex releases full phase II results with MDX-100 in rheumatoid arthritis

Selective glucocorticoid receptor modulator has less effect on bone biomarkers

Anti-Fas IgM monoclonal antibody ARG-098 decreases rheumatoid arthritis activity

A-940894 shows potent in vivo/in vitro anti-inflammatory activity

CB1 receptor antagonists reported by sanofi-aventis for the treatment of diabetes

Cancer Research Technology claims Chk1 inhibitors for the treatment of cancer

Novel anti-tuberculosis compounds described by French scientists

FDA approves Merck & Co.'s Gardasil for prevention of genital warts in males

Cenomed BioSciences presents anti-emetic candidate devoid of anxiogenic effects

Immunomedics reports results for UCB's new SLE candidate, epratuzumab

Ono obtains approval in Japan for anti-emetic drug, Emend

NexMed provides update on antifungal agent NM-100060

Cervarix approval in Japan for prevention of cervical cancer caused by HPV

Soligenix initiates confirmatory phase III orBec trial in acute gastrointestinal GVHD

Prograf approved in Japan for the additional indication of myasthenia gravis